论文部分内容阅读
近年来，先进国家围绕医疗质量经济学评价已在多层面上开展工作。本文扼要介绍了日本１９９７年以来关于医疗质量的政策和活动的情况，并重点对近年医疗质量经济学的新课题：评价的主体问题；以遗传基因重组技术等为代表的新技术问题加以评价，旨在为医学质量经济学评价的操作提供借鉴与思考。
In recent years, advanced countries have carried out work on multiple levels in the economic evaluation of medical quality. This article briefly introduces Japan’s policy and activities related to medical quality since 1997, and focuses on the new topics of medical quality economics in recent years: the subject of evaluation; and the evaluation of new technologies represented by genetic gene recombination technologies. The aim is to provide reference and thinking for the operation of medical quality economics evaluation.